ALMR logo

ALAMAR BIOSCIENCES INC

ALMRNASDAQ
πŸ† #1901 by market capUS Equity
$410.91β–Ό $15.12 (βˆ’3.68%)
Simulated price
πŸ””
Track ALMR
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 3.7%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$2.26B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+0.0%
Slowing
πŸ“ŠGross Margin
58.0%
Healthy
πŸ’΅FCF Margin
-64.8%
Thin
βš–οΈP/S Ratio
40.8x
Expensive
Otter Score
84
Good
No chart data available for ALMR.

Trading Snapshot

Day Range
$405.36 – $418.96
52-Week Range
$18.85 – $38.54
Volume
$3.87B
Avg Volume
$3.42B
Shares Outstanding
69.3M
Next Earnings
Nov 21, 2026

Fundamentals Snapshot

Annual Revenue
$74M
Last Q Revenue
$29M
P/E Ratio
-61.5
P/S Ratio
40.8x
EPS (TTM)
$-0.59
Dividend Yield
0.00%

Why Investors Own ALMR

  • βœ“High-growth profile β€” revenue up +47.3% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 34% gross margin and 9% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ALMR logo

ALAMAR BIOSCIENCES INC

ALMR
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$74Mβ–² +49.3% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
33.7%β–² +1.4% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$22Mβ–² +49.3% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$7Mβ–² +49.3% YoY
StockOtter Β· stockotter.space

About ALAMAR BIOSCIENCES INC

Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Good
84/100

Analyst Price Target

β“˜
Average Target
$516.74
β–² +25.8% Upside
High Target$588.09
Low Target$464.30
Based on 35 analysts

Latest News & Updates